Camrelizumab Combined with FOLFOX4 Regimen as First-Line Therapy for Advanced Hepatocellular Carcinomas: A Sub-Cohort of a Multicenter Phase Ib/II Study.
Hui LiShu-Kui QinYing LiuZhendong ChenZhenggang RenJianping XiongZhiqiang MengXiao ZhangLinna WangXiaojing ZhangJianjun ZouPublished in: Drug design, development and therapy (2021)
Camrelizumab combined with FOLFOX4 for first-line treatment of patients with aHCC showed good safety and tolerability, with promising preliminary antitumor activity.